Floatz logo

Lmb-100

Epithelioid Mesothelioma

National Cancer Institute (NCI)Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Epithelioid Mesothelioma cohort.

Asset / SponsorPhaseRating
Tofacitinib
National Cancer Institute (NCI)
Phase 1CC
Crs-207
Anza Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

Lmb-100 is also rated in:

lung adenocarcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
lung cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →